Does MDGL pay a dividend?

The cached stock data on this page does not show a positive dividend yield for MDGL. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does MDGL stock do?

Commercial-stage biopharmaceutical focused on commercializing Rezdiffra (resmetirom), the first approved oral liver-directed THR-beta agonist for MASH/NASH.

What is MDGL stock's price target?

This cached page does not contain a precise model fair value for MDGL.

The TradeMates model verdict for MDGL is HOLD with an investment score of 59/100. Treat this as a model signal to review, not a personal buy recommendation.

Is MDGL a good dividend stock?

MDGL is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

MDGL (MDGL) Stock Analysis

Q: Is MDGL stock a good investment?

The cached TradeMates AI model rates MDGL as HOLD with an investment score of 59/100. The model evaluates Madrigal Pharmaceuticals as a HOLD. First-mover dominance with Rezdiffra and multi-year revenue acceleration are tempered by elevated P/S multiples (9.67x) and ongoing operational cash burn. This is algorithmic model output, not personal investment advice.

Verdict: HOLD

First-mover advantage in MASH with Rezdiffra drives top-line expansion toward 2027 profitability, offset by cash burn and executive selling.

Investment score: 59/100

The model evaluates Madrigal Pharmaceuticals as a HOLD. First-mover dominance with Rezdiffra and multi-year revenue acceleration are tempered by elevated P/S multiples (9.67x) and ongoing operational cash burn.

Peers

EXEL
SMMT
BBIO
BMRN
HALO

Peer	P/E	P/B	P/S	EV/EBITDA	ROIC %	Net margin %
EXEL	17.56	7.86	5.96	13.85	—	0.35
SMMT	-15.91	22.01	0.00	-16.14	—	0.00
BBIO	-19.21	-5.35	19.47	-25.36	—	-1.01
BMRN	173.43	2.01	3.74	41.66	—	0.02
HALO	30.92	88.92	7.76	20.86	—	0.25

View the full interactive analysis